Stickit Technologies Inc. (CSE: STKT), a developer of proprietary cannabinoid and plant extract delivery technologies, has released a comprehensive corporate update disclosing leadership changes, capital restructuring, and an intellectual property portfolio update. The Vancouver-based company appointed Dr. Adi Zuloff-Shani as Chief Executive Officer effective July 10, 2026, and added two independent directors to its board. The announcement also confirms a non-brokered private placement raising CAD $722,100 and a debt restructuring transaction that reduced approximately $617,000 in insider-owed obligations to $380,000.

Key Points

  • Stickit Technologies Inc. (CSE: STKT) issued a multi-part corporate update on September 17, 2026
  • Dr. Adi Zuloff-Shani appointed CEO effective July 10, 2026; Gabriel Kabazo and Nir Eliyahu joined the board as independent directors
  • Non-brokered private placement closed at CAD $0.025 per unit, issuing 28,884,000 units and raising CAD $722,100 gross; warrants exercisable at CAD $0.025 for 36 months
  • Investors may be watching progress on joint venture formation in international recreational cannabis markets and commercial scaling of the flagship "Cannabis Sticks" product lines

Dr. Adi Zuloff-Shani Named CEO as STKT Reshapes Executive Leadership

Effective July 10, 2026, Dr. Adi Zuloff-Shani was appointed Chief Executive Officer of Stickit Technologies, succeeding Eli Ben-Haroosh, who resigned on April 1, 2026. Dr. Zuloff-Shani is a biomedical executive and immunologist with over two decades of experience in therapeutic R&D, drug discovery, and global regulatory strategy. She currently serves as CEO of Clearmind Medicine (NASDAQ: CMND). Joining the board on the same date, Gabriel Kabazo — an experienced public company finance professional — and Nir Eliyahu, a distribution and sales specialist, were appointed as independent, non-executive directors, with Ohad David remaining as Chair.

CAD $722,100 Private Placement and Insider Debt Restructuring Strengthen Balance Sheet

Stickit closed a non-brokered private placement issuing 28,884,000 units at CAD $0.025 per unit, generating gross proceeds of CAD $722,100. Each unit comprises one common share and one warrant exercisable at CAD $0.025 for 36 months from closing. Separately, Capitalink Ltd. acquired approximately $617,000 in debt previously owed by the company to corporate insiders for a restructured consideration of $380,000. The release states the company was not a direct party to that debt assignment agreement. The company also completed a 1-for-5 share consolidation to support capital restructuring flexibility, operating under CSE policy exemptions for issuers facing financial difficulty.

US Patent and Global Joint Venture Licensing Model Anchor IP Strategy

Stickit's intellectual property portfolio centres on its granted US Patent (US11582996 B2), covering methods and utensils for administering plant extracts at controlled amounts via smoking, as well as honey-and-plant-extract complexes. The company's commercialisation model targets jurisdictions where recreational cannabis is permitted, establishing joint ventures in which local partners invest in production facilities, manufacture finished products using Stickit-supplied raw materials, and sell through local channels. Each licensee receives exclusive territorial rights and pays a setup fee by funding the local production facility, the release states.